MediciNova, Inc. 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs. Its principal programs include MN-166 (ibudilast) for neurological disorders and COVID-19-related acute respiratory distress syndrome, and MN-001 (tipelukast) for fibrotic diseases. The unaudited report covers the three and six months ended June 30, 2020, filed July 28, 2020.
Key Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | None recognized | None recognized |
| Research, development and patents | $2.2 million | $3.4 million |
| General and administrative | $2.3 million | $4.0 million |
| Total operating expenses | $4.5 million | $7.4 million |
| Net loss | $4.5 million | $7.2 million |
| Net loss per share | $0.10 | $0.16 |
| Net cash used in operating activities | Not provided for the quarter | $5.0 million |
Cash and cash equivalents were $60.4 million at June 30, 2020, compared with $63.8 million at December 31, 2019. Working capital was $58.3 million. The filing reports no debt balances; total liabilities were $4.7 million, including $1.7 million of long-term deferred revenue. Stockholders’ equity was $71.1 million, and accumulated deficit was $376.2 million.
The filing does not present a meaningful operating margin because the company recognized no revenue and incurred operating losses. Stock-based compensation was $1.1 million for the quarter and $1.7 million for the six months.
Material Changes Versus Prior Comparable Period
- Second-quarter research, development and patent expense increased by $0.7 million to $2.2 million, primarily from higher clinical-trial costs, partially offset by lower performance-based stock compensation.
- Six-month research, development and patent expense increased by $0.3 million to $3.4 million, also reflecting higher clinical-trial costs.
- General and administrative expense declined by $0.4 million for the quarter and $2.1 million for the six months, mainly because of lower performance-based stock compensation.
- Six-month net loss improved by $1.4 million versus 2019, although the company remained unprofitable and generated no revenue.
- Six-month operating cash use increased to $5.0 million from $4.7 million. Financing cash inflows declined to $1.6 million from $4.1 million, primarily because 2019 included substantially greater option exercises.
- The company issued 209,671 shares under its 2019 at-the-market program for net proceeds of $1.2 million during the first six months. Through July 23, 2020, it sold an additional 109,365 shares for net proceeds of $0.6 million.
Outlook, Commentary, Risks and Unusual Items
Management expects substantial net losses to continue for the next several years as development programs advance. It expects research and development spending to increase during 2020. Management stated that available working capital was sufficient to fund operations at least through the end of 2021, but cautioned that this may not support all planned research and development activities.
COVID-19 reduced patient visits at certain clinical-trial sites, but management reported improving visit levels, continued enrollment and continued regulatory and site-initiation activities. The FDA accepted the IND for an MN-166 trial to evaluate prevention of COVID-19-related ARDS and advised that the proposed clinical investigation could proceed. Management did not expect a material negative impact on development plans, timelines or liquidity based on its assessment at the filing date, while acknowledging uncertainty regarding the pandemic, supply chains and operations.
Principal risks include the need for additional capital, continued absence of product sales, unsuccessful or delayed clinical trials, regulatory failure, reliance on MN-166 and MN-001, dependence on third-party manufacturers and clinical-trial providers, intellectual-property disputes, competition, commercialization and reimbursement uncertainty, loss of licensed rights, and COVID-19-related disruption. No material legal proceedings were reported.
Important Facts for Investors to Verify
- Whether the company can maintain its stated liquidity runway through the end of 2021 while expanding clinical development.
- Clinical enrollment, trial progress and regulatory milestones for MN-166, particularly the progressive MS, ALS and COVID-19-related ARDS programs.
- Future financing needs and the potential dilution from the $75.0 million 2019 ATM facility and outstanding options.
- The timing of any revenue recognition under the Kissei agreement; the remaining study timing was undetermined and no revenue was recognized in the reported periods.
- Whether COVID-19, supply-chain constraints or clinical-site disruptions materially alter development costs or timelines.
- The carrying values and future impairment risk associated with $9.6 million of goodwill and $4.8 million of in-process research and development.